Third-Party Payers Strike Out in Suits Alleging Off-Label Promotion Injuries
Executive Summary
While the pharma industry has plenty of litigation headaches there is good news on one front: courts are tossing out third-party payer suits alleging companies illegally marketed their drugs for off-label use
You may also be interested in...
No Defrauding Here: Third-Party Payers Bounced From Neurontin Off-Label Promotion Suit
Massachusetts U.S. District Judge Patti Saris has issued a string of harsh rulings against pharmaceutical companies for their off-label marketing practices. But her recent opinion in Neurontin (gabapentin) litigation shows cases against drug makers are not a slam dunk.
No Defrauding Here: Third-Party Payers Bounced From Neurontin Off-Label Promotion Suit
Massachusetts U.S. District Judge Patti Saris has issued a string of harsh rulings against pharmaceutical companies for their off-label marketing practices. But her recent opinion in Neurontin (gabapentin) litigation shows cases against drug makers are not a slam dunk.
Judge Tosses EPO Fraudulent Marketing Suit Against Amgen
A California court says third party payers did not show that Amgen fraudulently misrepresented the effectiveness of Epogen and Aranesp.